Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults
Authors:
- Christine DurierCDChristine Durier
- Odile LaunayOLOdile Launay
- Vincent MeiffrédyVMVincent Meiffrédy
- Yacine SaïdiYSYacine Saïdi
- Dominique SalmonDSDominique Salmon
- Yves LévyYLYves Lévy
- Jean-Gérard GuilletJGJean-Gérard Guillet
- Gilles PialouxGPGilles Pialoux
- Jean-Pierre AboulkerJAJean-Pierre Aboulker
- 24 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (7) , 1039-1049
Abstract
HIV-1 lipopeptides have been developed by the French National Agency for AIDS Research (ANRS) for use as candidate vaccine against HIV since 1994. Between 1996 and 2005, four different lipopeptide constructs were tested alone or in combination with recombinant canarypox HIV vaccines in 10 trials conducted in France. The aim of this study was to review clinical safety of HIV lipopeptides. A meta-analysis based on individual subject data examined clinical safety data collected in eight preventive trials and two therapeutic trials enrolling 200 HIV-1-uninfected healthy volunteers and 48 HIV-1-infected patients. Of 248 trial participants, eight (3.2%) did not complete follow-up: seven among the 200 healthy volunteers, and one among the 48 HIV-1 infected patients. During the 354 person-years of follow-up, 860 lipopeptides injections were administered. Local reactions were common. However, in trials where lipopeptides were tested without adjuvant and appropriate diluents, none of the vaccinees experienced severe local response. Systemic reactions were generally mild and transient. No grade 4 reaction was reported; 18 subjects experienced grade 3 systemic events related to the vaccination, mainly asthenia, fever, headache and arthralgia. Multivariate analysis showed that female sex, number of injections and diluent (more reactions in 5% glucose alone than in combination with Tris-HCl buffer) significantly increased systemic reactions related to the vaccination. These data demonstrate that reactogenicity and systemic safety of HIV lipopeptides vaccine are acceptable both in healthy volunteers and HIV-infected adults.Keywords
This publication has 16 references indexed in Scilit:
- Experience using MedDRA for global events coding in HIV clinical trialsContemporary Clinical Trials, 2006
- Participant Retention in Clinical Trials of Candidate HIV VaccinesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- The human immunodeficiency virus preventive vaccine research at the French National Agency for acquired immunodeficiency syndrome researchMemórias do Instituto Oswaldo Cruz, 2005
- Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes RecognizedJournal of Virology, 2003
- Safety profile of recombinant canarypox HIV vaccinesVaccine, 2003
- Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trialsVaccine, 2003
- Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteersAIDS, 2001
- Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidateVaccine, 1999
- Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studiesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996
- UVEITIS AFTER HEPATITIS B VACCINATIONThe Lancet, 1987